Search

Lisata Therapeutics

Slēgts

1.51 2.72

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.45

Max

1.53

Galvenie mērījumi

By Trading Economics

Ienākumi

1.6M

-2.9M

Peļņas marža

-2,954

Darbinieki

21

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

7.5M

14M

Iepriekšējā atvēršanas cena

-1.21

Iepriekšējā slēgšanas cena

1.51

Lisata Therapeutics Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. sept. 23:31 UTC

S&P Global Manufacturing PMI for South Korea set to release on October 1, 2026, amid cautious market expectations influenced by rising energy prices and geopolitical tensions.

2026. g. 26. sept. 23:31 UTC

S&P/Case-Shiller Home Price Index Set for Release with Anticipated 2.2% Growth Amid Mixed Market Sentiment and Economic Pressures

2026. g. 26. sept. 23:31 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to show growth trends amid recent fluctuations.

2026. g. 26. sept. 23:22 UTC

U.S. Q2 GDP Growth Rate Forecasted at +1.6% Amid Economic Concerns and Market Volatility Ahead of September 30 Release

2026. g. 26. sept. 23:22 UTC

Upcoming PCE Price Index release on September 30 raises inflation concerns amid rising commodity prices and geopolitical tensions.

2026. g. 26. sept. 23:22 UTC

U.S. Personal Spending Expected to Rise 0.8% in August Amid Caution Over Inflation and Consumer Confidence Decline

2026. g. 26. sept. 23:22 UTC

Upcoming U.S. Retail Inventories Ex Autos Report on September 30 Expected to Reflect Consumer Demand Amid Mixed Economic Signals.

2026. g. 26. sept. 23:22 UTC

U.S. Goods Trade Balance Report Set for Release Amid Anticipated $108.5 Billion Deficit and Positive Tariff Negotiations with China

2026. g. 26. sept. 23:22 UTC

US Personal Income Expected to Rise 0.4% in August Amid Economic Recovery and Inflation Concerns

2026. g. 26. sept. 23:22 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% Amid Mixed Investor Sentiment and Inflation Concerns Ahead of September Release

2026. g. 26. sept. 23:22 UTC

U.S. GDP Price Index Expected to Rise 0.064% Amid Mixed Economic Sentiment and Inflation Concerns Ahead of September Release

2026. g. 26. sept. 23:22 UTC

Core PCE Price Index MoM for August 2026 set to release on September 30, with a forecasted increase of 0.3%, amid cautious investor sentiment and rising treasury yields impacting Fed policy outlook.

2026. g. 26. sept. 23:22 UTC

U.S. PCE Price Index Release on September 30 Expected to Show 0.4% Monthly Increase Amid Inflation Concerns and Market Volatility

2026. g. 26. sept. 23:11 UTC

Cautious Market Anticipates 70,000 Job Increase in Upcoming ADP Employment Report Amid Recent Underperformance

2026. g. 26. sept. 23:11 UTC

Mexican Business Confidence Remains Cautious Ahead of October EMOE Release Amid U.S. Economic Concerns

2026. g. 26. sept. 23:11 UTC

Correlated Moves

Avalanche is trading higher, continuing its upward trend since Friday, while Ethereum remains little changed amid broader market support from easing oil prices and Treasury yields.

2026. g. 26. sept. 23:01 UTC

Canada's Preliminary Monthly GDP Release on September 29 Expected to Show Stability Amid Economic Challenges and Trade Tensions.

2026. g. 26. sept. 23:01 UTC

South Korea's October 1 export report expected to show continued strong growth, following August's impressive 68.7% surge driven by memory chip demand.

2026. g. 26. sept. 22:51 UTC

Japan's unemployment rate forecasted to drop slightly to 2.4% in August, amid cautious market optimism and concerns over currency depreciation and rising interest rates ahead of the October release.

2026. g. 26. sept. 22:51 UTC

South Africa's Balance of Trade report on September 30, 2026, expected to show continued trade surplus amid cautious optimism in exports and declining imports.

2026. g. 26. sept. 22:51 UTC

Germany's Inflation Rate Release on September 30, 2026: Consumer Confidence Declines Amid Rising Energy Prices and Economic Uncertainty.

2026. g. 26. sept. 22:51 UTC

Japan's Tankan Index Set for Positive Release Amid Cautious Market Optimism and Global Economic Pressures

2026. g. 26. sept. 22:51 UTC

Germany's Inflation Rate Expected to Rise 0.5% Amid Declining Consumer Confidence Due to Soaring Energy Prices

2026. g. 26. sept. 22:51 UTC

Macro News

The Russell 2000 Index is trading lower in after-hours, reflecting a slight decline since Friday's close, amid rising delinquency rates in the commercial real estate sector.

2026. g. 26. sept. 22:51 UTC

Macro News

The Dow Jones Index is lower in after-market trading, amid trade tariff discussions and rising delinquency rates in commercial real estate.

2026. g. 26. sept. 22:51 UTC

Macro News

The FTSE 100 Index has advanced modestly in after-market hours, following a U.S.-China tariff agreement on $30 billion in goods.

2026. g. 26. sept. 22:41 UTC

MBA 30-Year Mortgage Rate Hits 7.12%, Highest Since May, Amid Rising Treasury Yields and Inflation Concerns

2026. g. 26. sept. 22:40 UTC

Macro News

The DAX 30 Index is trading modestly lower in after-market hours, continuing its downward trend amid ongoing macroeconomic concerns and trade developments.

2026. g. 26. sept. 22:31 UTC

Japan's Industrial Production Expected to Rise 1.7% in August Amidst Cautious Optimism and Global Uncertainties

2026. g. 26. sept. 22:31 UTC

Japan's Retail Sales YoY data for August expected to rise 3.3% amid cautious optimism and inflation concerns, with market focus on currency valuation and global trends.

Salīdzinājums

Cenas izmaiņa

Lisata Therapeutics Prognoze

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

0

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pamatdarbības peļņa

$

Par Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.